Second Quarter FY 2026 Earnings Results January 6, 2026 Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives o ...

ATI-052: Anti-TSLP x IL-4Rα Bispecific Antibody Program Highly Potent and Bioactive Investigational Product Candidate January 6, 2026 Disclaimer and Cautionary Note Regarding Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "anticipate," "believe," "expect," "intend," "may," ...

Title text 2 Zumilokibart (APG777) Asthma Phase 1b Interim Results January 6, 2026 Disclaimers and Forward-looking Statements This presentation contains certain "forward-looking statements" within the meaning of applicable securities laws. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements about the potential for zumilokibart (APG777) in asthma; Apogee's plans for its current and future product candidates and programs; ...

Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout Analyst and Investor Webcast – January 6, 2026 1 Forward-Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of management of Alumis Inc. ("Alumis") in light of historical results and trends, current conditions and p ...

Pipeline and Milestones - Viridian aims to be a leading autoimmune company, starting with thyroid eye disease (TED)[6] - Viridian plans to submit a MAA for veligrotug in Q1 2026 and anticipates a PDUFA target date of June 30, 2026[19] - Topline data for REVEAL-1 (active TED) is expected in Q1 2026, and REVEAL-2 (chronic TED) in Q2 2026 for elegrobart[19] - An IND submission for an anti-TSHR subcutaneous product is anticipated in Q4 2026[10, 16, 19] - VRDN-008 healthy volunteer data is expected in 2H 2026[16, 19] Veligrotug (Anti-IGF-1R; Intravenous) - Veligrotug has a PDUFA target date of June 30, 2026, with Priority Review designation[10, 16, 18, 25] - In the THRIVE trial for active TED, veligrotug showed a 70% proptosis responder rate compared to 5% for placebo (p < 00001)[33, 95, 97] - In the THRIVE-2 trial for chronic TED, veligrotug showed a 56% proptosis responder rate compared to 8% for placebo (p < 00001)[35, 118] - 70% of proptosis responders in the THRIVE trial maintained their response at Week 52[33, 110, 111] Elegrobart (VRDN-003; Anti-IGF-1R; Subcutaneous) - Pivotal readouts for elegrobart in active TED REVEAL-1 study in Q1 2026 and chronic TED REVEAL-2 study in Q2 2026[10] - Phase 1 data showed an extended half-life of 40-50 days and approximately 4-fold increase in IGF-1 levels with subcutaneous elegrobart[134, 135] Financials - Viridian had $888 million in cash as of October 31, 2025, which, along with near-term DRI milestones and anticipated future revenues, is expected to fund current business plans through profitability[20] - The company secured access to up to approximately $900 million in capital in 2025[13] Market Opportunity - The annualized TED market is approximately $2 billion[10, 43] - The market sizes of MG and CIDP alone are projected to be over $112 billion by 2030[84, 85]

MSC INDUSTRIAL SUPPLY CO. INVESTOR PRESENTATION FISCAL 2026 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Statements in this presentation may constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact, that address activities, events or developments that MSC expects, believes or anticipates will or may occur in the future, including statements about results of operations and financial conditio ...

Debt Investor Presentation 6 January 2026 Contents 2 ▪ DNB – A brief overview ▪ The Norwegian economy ▪ Financial targets, performance and capital ▪ Loan book and asset quality ▪ ESG and sustainability ▪ Funding ▪ Appendices: ▪ Green bond framework ▪ Cover pool portfolio information and LCR eligibility ▪ ESG and digitalisation DNB – A brief overview 3 Jan - Sept 2025 Highlights ▪ Impairments NOK -1 950 mill 4 ▪ Resilient and solid earnings ▪ Pre-tax operating profit before impairment NOK 41 979 mill ▪ Profi ...

AI Market and Applications - AI is pervasive, with an estimated 5 billion people using AI daily within 5 years[14] - AI is expanding from cloud to personal computing and edge devices[18] - AI model innovation is accelerating compute demand, with training flops increasing 4x every year[28] AMD's AI Solutions for Data Center - AMD is building a blueprint for yotta scale infrastructure[31] - The AMD "Helios" AI Rack features 2.9 Exaflops of AI compute, 31 TB of HBM4 memory, and 43 TB/s scale out bandwidth[38] - AMD Instinct MI455X offers a 10x performance increase compared to MI355X[40] - AMD is extending its leadership roadmap with the next-gen MI500 series, targeting a >1000x AI performance increase in 4 years[52] AMD's AI Solutions for PCs - AMD is at the forefront of AI PC innovation, introducing the first x86 NPU[60] - AMD Ryzen AI 400 Series powers next-generation AI PCs, offering up to 1.3x faster multitasking and 1.7x faster content creation compared to Intel Core Ultra 9 288V[66] - AMD Ryzen AI Max+ demonstrates up to 1.4x faster AI performance compared to Apple Macbook Pro M5[77] and up to 1.8x faster content creation[78] - AMD Ryzen AI Max+ achieves up to 1.7x-1.8x tokens/sec per dollar compared to Nvidia DGX Spark in AI development tasks[81] AMD's Broader Impact - AMD powers over 1 billion gamers & creators[90] - AMD is the compute foundation for modern science, contributing to climate forecasting with an 85% reduction in time to generate forecasts[111] and antibody optimization[119]

@ TVIDIA "Everything Everywhere All at Once" AI Scales Beyond LLMs 80% of Startups Building on Open Models 1-in-4 OpenRouter Tokens Reasoning Generated by Open Models 2024 2025 Clara Earth-2 AI-Physics Model Open Models Kimi K2 - DeepSeek V3.2 Reach the Frontier ● ● - GPT-OSS 0 0 - Qwen Frontier Models . ● Nemotron ● . Open Models ● Jan 2025 Jan 2026 Jan 2023 Jan 2024 Release Date | | 160 M | | --- | --- | | | 140 M | | | 120 M | | | 100 M | | Monthly Hugging Face Downloads | 80 M | | | 60 M | | | 40 M | | ...

INVESTOR DAY Technical Excellence & Disciplined Execution Driving Superior Shareholder Returns January 2026 Unconventional Joey Wong – VP Unconventional Travis Tweit – VP Operations Conventional Chris Bullin – VP Conventional Travis Tweit – VP Operations Summary Grant Fagerheim – President & CEO Thanh Kang – Sr. VP & CFO 2 1 2 AGENDA Who We Are Grant Fagerheim – President & CEO Thanh Kang – Sr. VP & CFO Refer to Slide Notes and Advisories. 3 4 EXECUTIVE VALUE PROPOSITION Our simple, repeatable strategy of d ...